Introduction

The 2022 ESC/ERS guidelines significantly altered the landscape for mild pulmonary hypertension diagnosis by lowering the mean pulmonary artery pressure (mPAP) threshold to 20 mmHg. Consequently, clinicians must now identify patients earlier in the disease spectrum. Non-invasive tools like echocardiography are the primary screening method before proceeding to invasive right heart catheterisation (RHC). Identifying reliable metrics for this newly defined patient population is essential for effective clinical management.

Evaluating Metrics for Mild Pulmonary Hypertension Diagnosis

Recent findings from the EVIDENCE-PAH UK database highlight the importance of specific echocardiographic parameters. The study analyzed 1,991 individuals to evaluate tricuspid regurgitation velocity (TRV) and the TAPSE/SPAP ratio. Notably, these metrics perform excellently as predictors for mPAP thresholds of 20 mmHg and 25 mmHg. However, their predictive accuracy is slightly lower when specifically targeting the mild PH range of 21-24 mmHg. Furthermore, TRV and systolic pulmonary artery pressure (sPAP) values typically increase alongside hemodynamic severity. Therefore, these tools remain indispensable for initial screening despite their limitations in extremely mild cases.

The Prognostic Value of TAPSE/SPAP

One of the most critical observations from the study involves the TAPSE/SPAP ratio. This metric reflects the coupling between the right ventricle and the pulmonary artery. In the EVIDENCE-PAH UK cohort, a lower TAPSE/SPAP ratio served as a significant predictor of mortality. This relationship held true across the entire PH spectrum, including the mild PH subgroup. Additionally, lower values of this ratio strongly correlate with higher hemodynamic categories. Consequently, clinicians should prioritize the TAPSE/SPAP ratio not just for diagnosis but also for long-term risk stratification.

Practical Considerations for Clinicians

Early identification of mild hemodynamic changes allows for more frequent monitoring and intervention. While echocardiography remains a gateway, the study suggests that the 21-24 mmHg range presents unique diagnostic challenges. Specifically, the area under the curve (AUC) for these metrics was lower for mild cases compared to established PH. Ultimately, integrating clinical symptoms with these echo metrics provides the most robust path forward. Healthcare providers should maintain a high index of suspicion when echo metrics indicate borderline elevations.

Frequently Asked Questions

How has the definition of pulmonary hypertension changed recently?

The 2022 ESC/ERS guidelines redefined pulmonary hypertension as a mean pulmonary artery pressure (mPAP) greater than 20 mmHg at rest. Previously, the threshold for diagnosis was 25 mmHg.

Why is the TAPSE/SPAP ratio used in pulmonary hypertension screening?

The TAPSE/SPAP ratio provides an estimate of right ventricular-pulmonary arterial coupling. It is a powerful non-invasive marker that helps predict hemodynamic severity and patient mortality.

Can echocardiography confirm a diagnosis of mild pulmonary hypertension?

Echocardiography is a vital screening tool that estimates pressures, but right heart catheterisation remains the gold standard for confirming the diagnosis of pulmonary hypertension.

Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Karia N et al. Significance of echocardiographic metrics including TRV and TAPSE/SPAP in mild haemodynamic pulmonary hypertension - data from EVIDENCE-PAH UK. Echo Res Pract. 2026 Jun 08. doi: undefined. PMID: 42252485.

2. Humbert M et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022;43(38):3618-3731.